Home-based Exercise in Renal Transplant Recipients

Not Applicable

Active, not recruiting

• Conditions: Kidney Transplant; Complications

• Registration Number: NCT04123951
• Lead Sponsor: University of Leicester

Brief Summary

Although patients who have received a kidney transplant have better health than patients on dialysis, heart problems are still the commonest cause of death for kidney transplant recipients. This is because diseases like high blood pressure and diabetes are more common in patients with kidney transplants as well as factors related to having kidney disease itself and the medications transplant recipients have to take to stop them rejecting their transplanted kidney. Exercise is known to help with heart disease in lots of conditions and improves many of the risk factors known to cause heart disease in kidney transplant recipients. This study will investigate whether an individualised, home-based, exercise program improves heart disease in kidney transplant recipients. The study is a randomised controlled trial, with half the patients completing the 12 week exercise programme and the other half continuing with their normal care. The investigators will use detailed MRI scans to assess patient's hearts and blood vessels at the start and end of the study. The investigators will also assess changes in physical function, exercise capacity, blood markers of heart disease, changes in body type and quality of life measures assessed with questionnaires.

Detailed Description

Kidney transplantation confers a significant survival advantage over remaining on dialysis, but CVD remains the leading cause of death for RTRs and of graft loss. Acute myocardial infarction accounts for 15-20% of CVD-related deaths in RTRs, but sudden cardiac death, or death from fatal arrhythmia account for at least double this number, suggesting classical atheromatous coronary artery disease driven by traditional cardiometabolic risk factors, is not the dominant driving force of CVD in RTRs. Non-traditional cardiometabolic risk factors including endothelial dysfunction, systemic inflammation, acute rejection, anaemia and deranged bone-mineral metabolism are of at least equal importance in the pathogenesis of CVD in RTRs and drive pathological changes in cardiovascular structure and function that associate strongly with mortality. This is further illustrated by the fact that traditional CVD risk-stratification tools dramatically underestimate cardiovascular risk in patients with CKD, coronary revascularization does not improve outcomes for RTRs as it does in the general population and cardiac events are more likely to be fatal in RTRs than the general population. Immunosuppressive agents are well known to drive traditional CVD risk factors, but also drive non-traditional cardiometabolic risk factors. Cost-effective, deliverable interventions are needed to address the burden of CVD in RTRs by targeting traditional and non-traditional risk factors. Supervised exercise interventions in RTRs improve cardiorespiratory fitness and a variety of traditional and non-traditional risk factors for CVD, including metabolic profile, vascular stiffening, central adiposity and inflammatory cell and cytokine profiles, but are not realistically deliverable in the current financial climate. Home-based exercise training programs have been shown to be deliverable in patients on dialysis and patients undergoing cardiac rehabilitation, but the effectiveness and deliverability of home-based exercise interventions are largely untested in RTRs. It cannot be assumed such programs will be acceptable to RTRs, whose home-lives, social and occupational circumstances are significantly different to dialysis and cardiac patients. Many RTRs have had enforced sedentary lifestyles prior to transplantation as dialysis patients and their goals for rehabilitation as well as the disease processes at work are different to both dialysis and cardiac patients.

There are limited data on whether exercise-induced improvements in cardiometabolic risk translate into improvements in cardiovascular structure and function in RTRs. CMR is able to measure multiple clinically pertinent aspects of CVD processes in RTRs that relate closely to outcome with great accuracy, including:

* left ventricular hypertrophy

* myocardial fibrosis

* aortic stiffness

* coronary artery function

* myocardial steatosis

* subclinical systolic and diastolic dysfunction

This pilot randomised clinical trial will assess the deliverability of a combined aerobic and resistance, home-based, exercise intervention in RTRs. It will define recruitment and dropout rates from this newly designed, home-based, intervention and baseline values for CMR measures that assess prognostically important aspects of CVD in RTRs for the first time. Furthermore, it will test the effects of the intervention on traditional and novel CMR outcome measures that assess prognostically important aspects of CVD that relate directly to cardiovascular outcomes for the first time, providing estimates of effect-sizes on outcome measures. These data will be used to inform the design of a future, definitive study. This study will further the investigator's ability to make objective measures of cardiovascular health in RTRs, with the opportunity to compare CMR measures with traditional measures of cardiovascular fitness. The qualitative component of this study will refine the exercise intervention to maximize uptake in future studies and adoption into clinical practice.

Study Timeline

• Study First Submitted: 2019-09-16
• Study First Submitted QC: 2019-10-10
• Study First Posted: 2019-10-11
• Study Start: 2020-01-30
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-04
• Last Update Posted: 2024-12-09
• Primary Completion: 2027-06-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Age great than 18 years old
• Prevalent RTR longer than 1year
• Able and willing to give informed consent
• Increased cardiometabolic risk, with at least one of:

Diabetes mellitus Dyslipidaemia Hypertension History of ischaemic heart disease or cerebrovascular disease Obesity (BMI above 30)

Exclusion Criteria

• Unable to undertake exercise due to physical or psychological barriers
• Unable to undergo CMR scanning (incompatible implants, claustrophobia, allergy to agents)
• Contraindication to exercise training (American College of Sports Medicine guidelines)
• Female participants who are pregnant, lactating, or planning pregnancy during the course of the study.
• Scheduled elective surgery or other procedures requiring general anaesthesia during the study.
• Any other significant disease or disorder (i.e. significant co-morbidity including unstable hypertension, potentially lethal arrhythmia, myocardial infarction within 6 months, unstable angina, active liver disease, uncontrolled diabetes mellitus (HbA1c greater than or equal to 9%), advanced cerebral or peripheral vascular disease) which, in the opinion of the patient's own clinician the Principle Investigator may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• Inability to give informed consent or comply with testing and training protocol for any reason.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in aortic distensibility (mmHg-1×10-3)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in ejection fractions (%)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in Aortic pulse wave velocity (m/s)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in native and post-contrast T1 mapping time (ms)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in Myocardial systolic-strain (%)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in peak early-diastolic strain rate (%s-1)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in left/right ventricular volumes (ml)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in Myocardial and hepatic triglyceride content (%)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)
Change in Left ventricular mass (g/m)	Baseline and 12 weeks	Measured using multi-parametric cardiac MRI (CMR)

Secondary Outcome Measures

Name	Time	Method
Number of participants lost to follow up	Post 12 week intervention	This is the number of participants leaving the trial due to being uncontactable
Aerobic Capacity (change)	Baseline, 2 weeks, 4 weeks and 12 weeks	Measured by cardiopulmonary exercise test which produces V02 (maximal oxygen uptake) in both l/min and ml/kg/min. This is a measure of a participants aerobic capacity.
Lower limb strength (change)	Baseline and 12 weeks	Dynamometry
Number of participants dropping out of the trial	Post 12 week intervention	Otherwise known as the attrition rate
Balance (change)	Baseline and 12 weeks	Measured using a 'wii-fit' style board. Better balance is an idicator of falls risk
Number of exercise sessions completed per week	Post 12 week intervention	This will assess adherence to the intervention
Number of adverse events	Post 12 week intervention	This is a measure of the trial safety
Habitual Physical Activity (change)	Baseline and 12 weeks	Via accelerometry
Gait speed (change)	Baseline and 12 weeks	Gait speed is measure as the time taken to walk 4 meters. Slower speeds have been linked to higher mortality risk
Recruitment Rate	Post 12 week intervention	The feasibility of recruitment and interest of patients is an essential component of whether a full trial is feasible. The number of eligible patients and number of consented will be recorded. Monthly recruitment rate and the time taken to recruit 10 (25%), 20 (50%), 30 (75%), and 40 (100%) patients will be recorded.
Timed up and go test (TUAG)(change)	Baseline and 12 weeks	To determine fall risk and measure the progress of balance, sit to stand and walking. Patient sits and then the time taken to stand up and walk 3 meters and return is measured. If a patient took 14 seconds or longer he or she was classified as high-risk for falling
Upper Limb Strength (change)	Baseline and 12 weeks	Hand grip
Change in circulation markers of systemic inflammation	Baseline and 12 weeks	Blood Sampling including but not limited to IL-6, CRP, IL-10, TNF-Alpha
Muscle Elasticity (change)	Baseline and 12 weeks	Muscle elasticity will be measures using a MyotonPro device
Lower limb endurance (change)	Baseline and 12 weeks	Sit to stand 60 test measuring how many 'sit to stands' can be performed in 60 seconds
Body fat % (change)	Baseline and 12 weeks	Body fat measured using bio electrical impedance analysis
Weight (change)	Baseline and 12 weeks	Weight measured in kg
Height	Baseline	Height measured in meters
Muscle quality using Ultrasound Imaging (change)	Baseline and 12 weeks	fat thickness (mm)

Trial Locations

Locations (1)

University Hospital Leicester NHS Trust; 🇬🇧 Leicester, Leicestershire, United Kingdom